BioNotebook: Halozyme falters; Baxter acquires Chatham; Celgene buys Acceleron shares; and IPOs lose momentum
This article was originally published in Scrip
Halozyme Therapeutics closed down 27.3% at $8.43 per share on 4 April after it revealed a temporary halt for an ongoing Phase II clinical trial testing the San Diego-based company's PEGPH20 in pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.
You may also be interested in...
While some companies rushed into gene therapy and exited after a single setback, Asklepios BioPharmaceutical quietly advanced its programs, identifying challenges and overcoming them one at a time. Now, it's ready to advance multiple programs into the clinic.
Roche's emicizumab, Alnylam's fitusiran and multiple gene therapies may soon steal market share from established clotting factors sold by Shire, Novo Nordisk and others, but safety is a key consideration for physicians and patients.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.